[1]Serrano-Pozo A, Das S, Hyman B T. ApoE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20(1): 68-80.
[2]Lanfranco M F, Ng C A, Rebeck G W. ApoE lipidation as a therapeutic target in Alzheimer's disease[J]. Int J Mol Sci, 2020, 21(17): 6336.
[3]汪道文, 曾和松. 心血管内科疾病诊疗指南[M]. 3版. 北京: 科学出版社, 2013.
[4]中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国各类主要脑血管病诊断要点2019[J]. 中华神经科杂志, 2019, 52(9): 710-715.
[5]蔡璟浩, 周健. 《2021年美国糖尿病学会糖尿病医学诊疗标准》解读[J]. 中国医学前沿杂志: 电子版, 2021, 13(2): 13-23.
[6]中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 血脂异常基层诊疗指南 (实践版·2019)[J]. 中华全科医师杂志, 2019, 18(5): 417-421.
[7]于世英, 胡国清. 肿瘤临床诊疗指南[M]. 3版. 北京: 科学出版社, 2013.
[8]Song Y Q, Stampfer M J, Liu S M. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease[J]. Ann Intern Med, 2004, 141(2): 137-147.
[9]Zhong Z X, Wu H M, Li B, et al. Analysis of SLCO1B1 and ApoE genetic polymorphisms in a large ethnic Hakka population in southern China[J]. J Clin Lab Anal, 2018, 32(6): e22408.
[10]Goldberg T E, Huey E D, Devanand D P. Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies[J]. Nat Commun, 2020, 11(1): 4727.
[11]Zhang M D, Gu W, Qiao S B, et al. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls[J]. PLoS One, 2014, 9(4): e95463.
[12]王瑾, 陈韬, 刘连, 等. ApoE和SLCO1B1基因多态性与冠心病的相关性[J]. 心脏杂志, 2018, 30(2): 150-153.
[13]张晋霞, 张志勇, 刘斌, 等. 汉族人群载脂蛋白E基因多态性与缺血性脑卒中相关性的Meta分析[J]. 中西医结合心脑血管病杂志, 2017, 15(14): 1700-1703.
[14]Pei A N, Nossa C W, Chokshi P, et al. Diversity of 23S rRNA genes within individual prokaryotic genomes[J]. PLoS One, 2009, 4(5): e5437.
[15]Wang J Y, Zhang L, Liu J, et al. Metabolic syndrome, ApoE genotype, and cognitive dysfunction in an elderly population: a single-center, case-control study[J]. World J Clin Cases, 2021, 9(5): 1005-1015.
[16]Sinclair L I, Pleydell-Pearce C W, Day I N M. Possible positive effect of the APOE ε2 allele on cognition in early to mid-adult life[J]. Neurobiol Learn Mem, 2017, 146: 37-46.
[17]Guo T T, Zhang D H, Zeng Y Z, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease[J]. Mol Neurodegener, 2020, 15(1): 40.
[18]Ogura M, Toyoda Y, Sakiyama M, et al. Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach[J]. Hum Cell, 2021, 34(6): 1727-1733.
[19]Romero-Moraleda B, Cupeiro R, González-Lamuño D, et al. Impact of APOE2allele on lipid profile change after a weight loss program[J]. Nutr Hosp, 2018, 35(2): 305-311.
[20]Kim H, Devanand D P, Carlson S, et al. Apolipoprotein E genotype e2: neuroprotection and its limits[J]. Front Aging Neurosci, 2022, 14: 919712.
[21]Bocksch L, Stephens T, Lucas A, et al. Apolipoprotein E: possible therapeutic target for atherosclerosis[J]. Curr Drug Targets Cardiovasc Haematol Disord, 2001, 1(2): 93-106.
[22]Martens Y A, Zhao N, Liu C C, et al. ApoE cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias[J]. Neuron, 2022, 110(8): 1304-1317.
[23]Rühlmann C, Dannehl D, Brodtrück M, et al. Neuroprotective effects of the FGF21 analogue LY2405319[J]. J Alzheimers Dis, 2021, 80(1): 357-369.
|